Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Nektar TherapeuticsNASDAQ: NKTR

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $12.77M fell 25.2% year over year, ahead of the -31.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.

Context

  • Selling, general & admin amounted to 124.3% of revenue in FY2025, up 46.4 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 13 analysts of $41.26M (-39.9%) for the fiscal year ending Dec 2026, a slowdown from the -10.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$12.77M-3.9% QoQ
Last fiscal yearDec 2025
$68.67M-10.5% YoY
LTMJun 2026
$53.31M-31.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%-34.1%-8.9 pp
1 year-10.5%-39.9%-29.4 pp
3-year CAGR-9.4%-17.9%-8.5 pp
5-year CAGR+22.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
68.67M USD
Year-over-year change
-10.5%
4-year CAGR
-13.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -31.2% is the lowest of 10, against a peer median of -6.3%.
  • Selling, general & admin amounts to 97.7% of revenue for NKTR, versus a peer median of 90.6%.
NKTR Competitors
Selling, General & Admin for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$151.41M USD-3.4%—39.2%
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M USD-7.8%+1.9%90.6%
CHRSCoherus Oncology, Inc.LTM Mar 2026$95.58M USD-30.3%-20.7%203.9%
XNCRXencor, Inc.LTM Jun 2026$65.29M USD+5.1%+10.3%62.2%
IMTXImmatics N.V.LTM Mar 2026€53.63M EUR+14.4%+12.3%143.8%
NKTRNektar TherapeuticsLTM Jun 2026$53.31M USD-31.2%-9.4%97.7%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
ANLAdlai Nortye Ltd.LTM Jun 2024$14.78M USD—-14.4%227.7%
IPHAInnate Pharma S.A.FY2025€11M EUR-7.8%-8.7%394.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$10.49M USD+24.0%+4.5%—
CGENCompugen Ltd.LTM Mar 2026$9.36M USD-6.3%-5.7%12.9%
Peer median (excluding NKTR) —-6.3%-5.7%90.6%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.